MARKET

NVAX

NVAX

Novavax Inc
NASDAQ
4.090
+0.140
+3.54%
After Hours: 4.090 0 0.00% 19:59 04/26 EDT
OPEN
3.970
PREV CLOSE
3.950
HIGH
4.130
LOW
3.920
VOLUME
3.02M
TURNOVER
0
52 WEEK HIGH
11.36
52 WEEK LOW
3.532
MARKET CAP
572.41M
P/E (TTM)
-0.7561
1D
5D
1M
3M
1Y
5Y
WHO picks JN.1 variant for next set of COVID vaccines
Healthcare WHO picks JN.1 variant for next set of COVID vaccines. World Health Organization recommended drugmakers to update their vaccine formulations to reflect the currently dominant SARS-CoV-2 variant, Jn.1. The currently approved vaccines are designed to target the XBB.5 Omicron subvariant.
Seeking Alpha · 1d ago
NOVAVAX :PREPARED TO DELIVER PROTEIN-BASED NON-MRNA JN.1 COVID-19 VACCINE IN LINE WITH WHO RECOMMENDATION THIS FALL
Reuters · 2d ago
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
NASDAQ · 6d ago
Weekly Report: what happened at NVAX last week (0415-0419)?
Weekly Report · 6d ago
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
Two biotech companies are expected to soar over the coming 12 months. Iovance Biotherapeutics recently won accelerated approval for its first cancer treatment. Novavax is a vaccine company that could be a growth stock in the future. Both companies offer great long-term prospects. Wall Street is optimistic about two of these companies.
The Motley Fool · 04/21 09:08
What's in Store for Biogen (BIIB) This Earnings Season?
NASDAQ · 04/19 13:39
NOVAVAX TO SUPPLY UPDATED COVID-19 VACCINE TO PRIVATE HEALTHCARE PROVIDERS IN THE UNITED KINGDOM
Reuters · 04/18 12:00
BUZZ-U.S. STOCKS ON THE MOVE-Snap One, Encore Wire, Centene
The Dow Jones Industrial Average was down 0.45% on Monday. Goldman Sachs boosted by robust gains. Snap One, Encore Wire, Centene were among the top stocks on the NYSE. The S&P 500 and Nasdaq Composite both fell on the day. U.S. Retail sales were stronger than expected.
Reuters · 04/15 17:48
More
About NVAX
Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Company’s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Webull offers Novavax Inc stock information, including NASDAQ: NVAX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVAX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading NVAX stock methods without spending real money on the virtual paper trading platform.